Saturday 17 October 2026 Export MIRM’s income statement to Excel — free account

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024. In the quarter to June 2026, revenue grew 37.9%, EPS fell 783.3%, free cash flow fell 681.5% and total debt rose 142.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

80.14 2.25 −2.73%

Follow MIRM

Alert me

Market cap: $5.4B
P/E: 0.0×
Fwd P/E: −6.0×
Dividend yield: —
F-score: 6/9
Altman Z: 4.42
Beneish M: −2.46
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 9.00

Total sells 42.20

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	1	—	—	—	—	—	—	—	—	—
Sell	1	4	11	4	6	1	1	4	3	4	3	—

Insider Ownership 15.12%

Capital & Financial Ratios $m

Market Cap 5,350.00

Revenue 618.07

Net Income (860.21)

Free Cash Flow (273.74)

Net Debt 311.79

Current Ratio 2.86

Debt/Equity (71.97)

P/E ratio 0.00

Fwd P/E (5.97)

P/S ratio 8.22

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (3,117.67%)

Next Y EPS Growth 95.37%

Next Y revenue growth 33.62%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 44.26%

10-year low 10-year high

EV/Sales against its own 10 years 54.25%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	286	280	383	438
Receivables	68	78	123	145
Inventory	22	22	25	26
Other	—	—	—	—
	388	393	550	636

	2023	2024	2025	Q'26
Payables	7	15	10	23
ST’ Debt	—	—	—	—
Other	—	—	—	25
	87	127	206	223

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	89.13%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	12.83%	30.36%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	160	176	—	—	—
’25	112	128	133	149	521
’24	69	78	90	99	337
’23	32	37	48	70	186
’22	13	17	19	28	77

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(229)	(44)	—	—	—
’25	(2)	12	40	6	56
’24	15	(4)	4	(5)	10
’23	(19)	(17)	(18)	(17)	(71)
’22	(40)	(20)	(26)	(34)	(120)
’21	(25)	(40)	(34)	(33)	(133)
’20	(18)	(17)	(17)	(36)	(89)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(239)	(69)	—	—	—
’25	(2)	12	39	5	55
’24	15	(15)	(6)	(5)	(11)
’23	(34)	(17)	(18)	(22)	(91)
’22	(40)	(20)	(26)	(35)	(120)
’21	(25)	(40)	(34)	(52)	(152)
’20	(18)	(17)	(17)	(36)	(89)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(13.43)	(1.06)	—	—	—
’25	(0.30)	(0.12)	0.05	(0.11)	(0.47)
’24	(0.54)	(0.52)	(0.30)	(0.49)	(1.85)
’23	(0.80)	(1.94)	(0.57)	(0.66)	(3.94)
’22	(1.17)	(0.84)	(1.02)	(0.99)	(4.02)
’21	(1.68)	(1.45)	(1.55)	1.91	(2.77)
’20	(0.86)	(0.93)	(0.86)	(1.43)	(4.09)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	6.51	9.14	12.82	14.63	18.46	23.14	36.88	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	28.31	27.43	22.14	30.55	35.56	48.89	82.58
People
People	Employees	—	—	20	33	68	137	196	264	322	372
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.14	0.39	0.71	1.05	1.40
Income, $m
Income, $m	Revenue	—	—	—	—	—	19	77	186	337	521
	Gross margin, %	—	—	—	0.00	0.00	90.06	83.94	74.76	75.77	80.77
	EBT	—	—	(17)	(53)	(103)	(84)	(142)	(162)	(87)	(21)
	EBT margin, %	—	—	0.00	0.00	0.00	(438.66)	(184.36)	(87.15)	(25.80)	(4.11)
	Net income	—	0	(17)	(53)	(103)	(84)	(136)	(163)	(88)	(23)
	Depreciation	—	—	—	0	1	1	3	12	25	26
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.63	2.28	4.56	7.09	10.39
	Earnings	—	—	(19.30)	(4.58)	(4.09)	(2.77)	(4.01)	(3.94)	(1.85)	(0.47)
	Cash flow	—	—	(0.41)	(3.43)	(3.53)	(4.38)	(3.55)	(1.74)	0.22	1.11
	Capex	—	—	(8.34)	(0.02)	(0.01)	(0.63)	(0.01)	(0.49)	(0.44)	(0.02)
	Free cash flow	—	—	(8.76)	(3.45)	(3.54)	(5.01)	(3.56)	(2.23)	(0.22)	1.09
	Book value	—	—	(19.26)	11.35	6.82	3.96	4.20	6.08	4.75	6.27
	Shares, m	—	—	1	11	25	30	34	41	48	50
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	0.00	8.47	6.59	5.83	7.61
	P/B	—	—	—	—	—	4.02	4.59	4.94	8.71	12.60
	EV/Sales	—	—	—	—	—	0.00	8.33	6.69	5.92	7.47
	EV/FCF	—	—	—	—	—	(3.46)	(5.33)	(13.70)	(127.19)	130.27
Cash, $m
Cash, $m	Operating cash flow	—	—	0	(39)	(89)	(133)	(120)	(71)	10	56
	Capex	—	—	(7)	0	0	(19)	0	(20)	(21)	(1)
	Free cash flow	—	—	(8)	(40)	(89)	(152)	(120)	(91)	(11)	55
Balance, $m
Balance, $m	Working capital	—	—	50	106	218	124	125	300	266	344
	Total debt	—	—	—	3	50	132	142	306	308	310
	Net debt	—	—	(52)	(113)	(182)	(25)	(10)	20	28	(74)
	Shareholders’ equity	—	—	(17)	130	172	120	142	249	226	315
Returns, %
Returns, %	ROA	—	—	(66.76)	(52.90)	(53.29)	(31.37)	(41.90)	(32.70)	(13.35)	(3.09)
	ROIC	—	—	0.00	(201.97)	0.00	(113.49)	(62.17)	(25.38)	(21.61)	(5.74)
	ROE	—	—	(30.69)	(92.98)	(68.29)	(57.47)	(103.46)	(83.65)	(37.08)	(8.65)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IMVT Immunovant, Inc.	$5.7B	— (loss-making)	—	—	n/m	−5.96% (below 0%: shrinking)	0.00%	0.00%	Compare
KOD Kodiak Sciences Inc.	$5.5B	— (loss-making)	—	—	n/m	−33.86% (below 0%: shrinking)	0.00%	0.00%	Compare
CGON CG Oncology, Inc.	$5.5B	— (loss-making)	— (loss-making)	+2,125.00% (above 0%: growing)	n/m	−67.60% (below 0%: shrinking)	(239.24%)	(7,467.68%)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)
ERAS Erasca, Inc.	$5.2B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%	Compare
CRSP CRISPR Therapeutics AG	$5.0B	— (loss-making)	— (loss-making)	+1,041.37% (above 0%: growing)	n/m	+26.19% (above 0%: growing)	100.00%	(1,151.84%)	Compare
TVTX Travere Therapeutics, Inc.	$5.0B	— (loss-making)	196×	+48.17% (above 0%: growing)	n/m	+604.22% (above 0%: growing)	98.72%	2.33%	Compare
Median of peers	$5.2B	—	—	+101.55%	—	−5.31%	0.00%	0.00%

All 614 Biotechnology stocks →

Mirum Pharmaceuticals, Inc. (MIRM) key facts

Strength: Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
Mirum Pharmaceuticals, Inc. (MIRM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MIRM traded at $80.14, a market capitalization of $5.4 billion.
Return on equity was −8.65% and debt-to-equity -71.97.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 4.42 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.